Lanifibranor

Terray Therapeutics enhances AI platform tNova for small molecule solutions; Kailera Therapeutics launches with $400M Series A for obesity treatments; Seaport Therapeutics raises $225M Series B for bioavailability and hepatotoxicity reduction; Aktis Oncology secures $175M Series B for radiopharmaceuticals; Alpha-9 Oncology raises $126.3M Series C for radiopharmaceuticals; Terray Therapeutics closes $120M Series B for AI platform; Triveni Bio raises $115M Series B for monoclonal antibody inhibitor and pancreatitis treatment; Purespring Therapeutics secures $105M Series B for kidney disease; Inventiva receives $101.5M financing for Phase 3 trial of metabolic dysfunction-associated steatohepatitis; Cytovale raises $100M Series D for sepsis diagnostic test; Judo Bio launches with $100M Series A for oligonucleotide medicines for the kidney; Resolution Therapeutics raises $82.4M Series B for end-stage liver disease therapy; Nuclera completes $75M financing for protein expression system; Nura Bio raises $68M Series A for brain-penetrant SARM1 inhibitor; Basecamp Research secures $60M Series B for data collection and AI development; Constructive Bio raises $58M Series A for custom genomic writing technology; Genespire closes $52M Series B for methylmalonic acidemia clinical trial; 858 Therapeutics raises $50M Series B for small molecule therapeutics; LoQus23 secures $43M Series A for allosteric small molecule MutSβ inhibitor; Arda Therapeutics gains $43M Series A for targeted cell depletion therapies; Enara Bio raises $32.5M Series B for TCR-based immunotherapies; MarchBio receives $28.4M Series A for CAR-T cell therapy; Phare Bio and Collins Lab awarded $27M for AI discovery platform and novel antibiotics; Alyssum Therapeutics raises $26M Series A for first-in-class small molecule CMTR2 inhibitor; Passkey Therapeutics emerges with $20M seed funding for complex disease therapies; Lymphatica Medtech SA raises $19.3M Series B for novel lymphedema treatment; MARAbio closes $19M Series A for blood test for autism diagnosis; Tolerance Bio secures $17.2M seed financing for thymus-based therapies; Shift Bioscience raises $16M seed funding for cell simulation AI platform; Mindpeak raises $15.3M Series A for commercialization of clinical diagnostic AI; C2N Diagnostics receives $15M financing for next-gen tests for tau tangle pathology; Booster Therapeutics launches with $15M financing for small molecule discovery platform; LIfT BioSciences raises $12.9M Series A for first-in-class allogeneic innate cell therapy; PhoreMost adds $12M to Series B for novel degrader programs; Sequentia Biotech closes $10.8M Series A for bioinformatics platform expansion.

Various biotech companies announced significant funding rounds for advancing next-gen therapies, diagnostic tests, and AI platforms, including Kailera Therapeutics for obesity treatments, Seaport Therapeutics for bioavailability enhancements, Aktis Oncology for radiopharmaceuticals, Alpha-9 Oncology for radiopharmaceuticals, Terray Therapeutics for AI-driven small molecule solutions, Triveni Bio for monoclonal antibody inhibitors, Purespring Therapeutics for kidney disease treatments, Inventiva for metabolic dysfunction-associated steatohepatitis, Cytovale for sepsis diagnostic tests, Judo Bio for oligonucleotide medicines, Resolution Therapeutics for end-stage liver disease therapies, Nuclera for protein expression systems, Nura Bio for brain-penetrant SARM1 inhibitors, Basecamp Research for programmable genetic medicines, Constructive Bio for custom genomic writing technology, Genespire for methylmalonic acidemia treatments, 858 Therapeutics for small molecule therapeutics, LoQus23 for allosteric small molecule MutSβ inhibitors, Arda Therapeutics for targeted cell depletion therapies, Enara Bio for TCR-based immunotherapies, MarchBio for CAR-T cell therapies, Phare Bio for AI-driven antibiotic discovery, Alyssum Therapeutics for CMTR2 inhibitors, Passkey Therapeutics for complex disease therapies, Lymphatica Medtech for lymphedema treatments, MARAbio for autism diagnosis, Tolerance Bio for thymus-based therapies, Shift Bioscience for cell simulation AI, Mindpeak for clinical diagnostic AI, C2N Diagnostics for tau tangle pathology tests, Booster Therapeutics for small molecule discovery, LIfT BioSciences for allogeneic innate cell therapies, PhoreMost for novel degrader programs, and Sequentia Biotech for bioinformatics platform expansion.

Inventiva announces LEGEND Phase 2 results evaluating lanifibranor with empagliflozin in MASH/NASH and T2D patients accepted as late breaker at AASLD's The Liver Meeting® 2024. Lanifibranor, Inventiva's lead candidate, is a pan-PPAR agonist targeting MASH/NASH treatment, with FDA Fast Track and Breakthrough Therapy designations.

Inventiva announced Phase 2 LEGEND results evaluating lanifibranor with empagliflozin in MASH/NASH and T2D patients accepted as late breaker at AASLD's 75th Liver Meeting 2024.

Inventiva announced that the results of the Phase 2 LEGEND trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and T2D, have been accepted as a late breaker for the 75th Annual AASLD The Liver Meeting 2024. Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule targeting all three PPAR isoforms for the treatment of MASH/NASH.

Inventiva secures €94.1 million of up to €348 million in equity financing to fund Phase 3 NATiV3 trial for lanifibranor in MASH, with over 1,100 patients enrolled; appoints Mark Pruzanski, MD as Chairman and Srinivas Akkaraju, MD, PhD as director.

Inventiva filed its 2024 Half-Year Report with the AMF, noting material uncertainty related to its going concern status. The report is available on Inventiva's and AMF's websites. Inventiva focuses on developing oral therapies for MASH/NASH and other unmet medical needs, with lanifibranor in pivotal Phase III trial for MASH/NASH.